Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FEASIBLE add-on factorial trial in Behçet's uveitis
ChiCTR2300071842Phase 3Not yet recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of adalimumab and aldesleukin in Behçet's disease (BD) (4 arms), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoint: Time to treatment failure. Planned start May 2023; status: not yet recruiting.
02
Drugs
adalimumabaldesleukin
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on ChiCTR2300071842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071842.